Abstract 5257
Background
A majority of patients with mCRC are not suitable for potentially curative resection and their management consists in palliative-intended chemotherapy (CT). Nevertheless, it is described that in patients who achieve complete response (CR) with CT alone or after multimodality treatment, median overall survival is significantly longer than in other patients. In combination with CT, anti-EGFR antibodies appear to be the biological agents of choice in order to reach the best response rate as long as tumors are RAS wild-type.To determine RAS and BRAF mutational status, we have already demonstrated the clinical validity and utility of circulating DNA (ctDNA) analysis using IntPlex® method. Selecting patients with this technology, we aim to investigate response rate and outcomes reached with panitumumab in combination with a standard (mFOLFOX6) or an intensified CT regimen (FOLFIRINOX) in RAS and BRAF wild-type (WT) metastatic patients.
Trial design
This is a national multicentric open-label randomized phase II trial. Key inclusion criteria are age between 18 and 75 years, ECOG PS 0 and 1, untreated synchronous or metachronous metastatic disease deemed unresectable with curative intent, RAS and BRAF WT tumor according to analysis of ctDNA by Intplex® technology. 209 patients will be randomized 2:1 to either FOLFIRINOX-panitumumab (N = 139) or mFOLFOX6-panitumumab (N = 70)(12 planned cycles in each arm). For each arm, two strata are planned according to disease-extent (non/liver limited disease). Primary endpoint is the CR rate defined as complete disappearance of metastatic lesions and CEA level normalization. It can be reached with CT alone or with a multimodal approach. Secondary endpoints are progression-free and overall survival, secondary resection rate, early tumor shrinkage, depth of response, safety, diagnostic performance of ctDNA analysis. On-treatment, an ancillary study assesses appearance of RAS mutations in ctDNA detected by Intplex® technology. The first patient was enrolled in October 2017 and > 20 sites are planned to recruit patients.
Clinical trial identification
NCT02980510.
Legal entity responsible for the study
UNICANCER GI.
Funding
Amgen.
Editorial Acknowledgement
Disclosure
T. Mazard: Research funding: Roche and Amgen; Honoraria: Amgen, Sanofi, BMS; Travel accommodations, expenses: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
4784 - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.
Presenter: Koji Takahashi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
767 - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
Presenter: Alexander Cortez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
938 - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
Presenter: Lihua Qiu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1
Presenter: xiaoxun Wang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4934 - Risk prediction of metastasis through study of circulating tumor cells
Presenter: Panagiotis Apostolou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3289 - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells
Presenter: Volodymyr Halytskiy
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4110 - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Presenter: Alexandra Tsidulko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1526 - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
Presenter: David Albert Bellver
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4862 - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients
Presenter: Zhang Min
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
Presenter: Filip Kohutek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract